TORONTO, April 10, 2012 (GLOBE NEWSWIRE) -- GeneNews Limited (TSX:GEN), a company focused on developing and commercializing blood-based biomarker tests for the early detection of diseases and personalized health management, announced that Enzo Clinical Labs, a division of Enzo Biochem, Inc. (NYSE:ENZ), has launched ColonSentry®, the world’s first blood test to assess an individual’s current risk for colorectal cancer.
